الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 161 |  |  |
| | | from | 161 | | |
Abstract
HCV is considered as a major public health problem in the world and particularly in Egypt due to the high prevalence of the HCV infection among the Egyptian population.
We have found that beside the impact of the HCV infection on the physical component due to the bad consequences on the liver and the resultant liver cell failure; it had also a psychological impact on the quality of life. And in order to assess this affection we used two of the tools for assessing the HRQoL; one of them was a generic tool which is SF 36 V2 and the other was a newly translated version to Arabic of the disease specific questionnaire CLDQ which originally developed at 1999 by Youonssi ZM.
The study was conducted on collaboration between the gastro-entrology and hepatology department in Agouza police hospital and Tropical department Ain shams university. The study was case control study included a total of 250 Patients divided in three groups of patients;
• group I included 50 HCV-negative subjects as a control.
• group II included 100 HCV patients before treatment and they are followed up after achieving the SVR12.
• group III included 100 HCV patients after treatment and achieving SVR.
And the study was conducted in the period between September 2018 to June 2019.
All patients were subjected to the following; careful history taking, thorough clinical examination and laboratory investigations: liver enzymes (AST and ALT), serum albumin, INR, total and direct bilirubin, complete blood count, viral markers (HCV-Ab and HBs-Ag), serum creatinine, AFP, PCR HCV RNA and Fibroscan was done to all patients to assess the stage fibrosis. Abdominal ultrasound was done for all cases then we administered the SF36 and CLDQ to all the participants in the study after their informed consent.
The 3 groups were age matched, the mean age was 37.2 (± 12.07) years in group I (control group), 36 (± 10.9) years in group II (post treatment), and 41.88 (±13.7) years in group III. Females represent 64% of group I, 29% of group II and 32% of group III.
Associated co-morbidities (diabetes and hypertension) were positive in 34% of group I, 14% group II and 31% group III. History of IV drug abuse was negative for group I, 8% for group II and 6% for group III.
We found that the HCV infection has an impact on the HRQoL and regarding our study we found a considerable decrease in the scores of the CLDQ and SF36 in patients with HCV in compared to control.
Also the severity of the liver disease determined the impact on the Qol as we found patients with significant fibrosis had a much worse scores also the degree of liver inflammation which delineated by the level of aminotransferases.
And the introduction of the DAAs as a treatment to HCV infection and its high SVR rates and its almost no side effects were a game changer in the battle with HCV and the effect on the HRQoL after the treatment with these new regimens was marvelous which is the aim of any clinical intervention.
Finally we provided a tool that measures the QoL in patients with chronic liver disease in Arabic language and this tool will be useful in the future in assessing the various medical interventions towards treating other hepatological diseases and gives us an accurate measure on the impact on QoL.